Abbott Laboratories stock (US0028241000): Shares hit 52-week low amid sector weakness and valuation debate

Abbott Laboratories stock has fallen to a 52-week low around $86, pressured by broader healthcare sector weakness and a sharp year-to-date decline, even as insiders add to their stakes.

Abbott Laboratories shares have dropped to a 52-week low near $86, reflecting a sharp pullback in one of the healthcare sector’s blue?chip names. On May 8, 2026, the stock closed at about $84.32, down roughly 3.1% on the day and more than 30% year?to?date, according to InvestingPro data cited by Investing.com as of May 8, 2026. Earlier in the week, Abbott shares had already touched a 52?week low of $86.15, underscoring how far the stock has retreated from its June 2025 high of $139.06, as reported by Barchart as of May 4, 2026.

Despite the price slump, Abbott remains a large, diversified healthcare player with a broad footprint across medical devices, diagnostics, nutrition and branded generics. The company’s trailing?12?month revenue has grown into the mid?$40?billion range, with full?year 2025 revenue reported at about $44.3 billion, up more than 5% versus 2024, according to Simply Wall St as of 2026. However, net income and earnings per share have come under pressure, with 2025 EPS around $3.73 versus roughly $7.70 in 2024, reflecting one?off or restructuring?related hits that have weighed on profitability even as sales expanded.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare, diversified medical products
• Headquarters/country: United States
• Core markets: United States, Europe, Asia and emerging markets
• Key revenue drivers: Medical devices, diagnostics, nutrition and branded generic pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: U.S. dollars

Abbott Laboratories: core business model

Abbott Laboratories operates a highly diversified healthcare portfolio that spans four main segments: medical devices, diagnostics, nutrition and pharmaceuticals. Within medical devices, Abbott is known for cardiovascular products such as coronary stents, structural heart devices and neuromodulation systems, as well as diabetes care technologies like continuous glucose monitors and insulin?delivery?adjacent solutions. The diagnostics segment includes point?of?care testing, laboratory instruments and rapid tests for infectious diseases and chronic conditions, giving Abbott exposure to both routine screening and acute?care settings.

The nutrition business focuses on pediatric and adult formulas, including specialized products for metabolic and gastrointestinal conditions, while the pharmaceuticals segment concentrates on branded generics and established medicines in emerging markets. This mix allows Abbott to combine relatively stable, recurring?demand businesses—such as nutrition and core diagnostics—with higher?growth niches like advanced cardiovascular devices and diabetes technology. The company’s global footprint and long?standing relationships with hospitals, labs and retailers underpin its ability to generate steady cash flows, even in periods of macroeconomic uncertainty.

Main revenue and product drivers for Abbott Laboratories

Within Abbott’s portfolio, medical devices and diagnostics are the primary growth engines, while nutrition and pharmaceuticals provide more stable, cash?generating streams. Recent full?year data show that revenue growth has been driven by continued demand for cardiovascular and diabetes?care products, as well as ongoing adoption of newer diagnostic platforms and tests, according to Simply Wall St as of 2026. At the same time, Abbott has been working through portfolio?related headwinds, including the impact of prior divestitures and one?time charges, which have compressed net income and EPS despite top?line expansion.

Analyst estimates for 2026 point to a modest rebound in earnings, with consensus EPS projected around $5.48 versus about $5.15 in 2025, implying low?single?digit growth, according to Barchart as of May 4, 2026. Quarterly estimates also suggest a gradual improvement, with expected EPS of roughly $1.28 for the June 2026 quarter and about $1.43 for the September 2026 quarter, reflecting mid? to high?single?digit year?over?year growth. These figures indicate that, while Abbott’s earnings trajectory has been bumpy, the underlying business is still expected to grow at a modest pace.

Why Abbott Laboratories matters for US investors

For US investors, Abbott Laboratories offers exposure to a large, dividend?paying healthcare conglomerate that is deeply integrated into the domestic healthcare system. The company’s devices and diagnostics are widely used in US hospitals and clinics, and its nutrition products are sold through major retail channels, giving it a strong presence in everyday consumer and clinical settings. As a New York Stock Exchange?listed stock, Abbott also benefits from high liquidity and broad index inclusion, which can make it attractive to both active and passive investors.

At current levels, Abbott trades at a forward price?to?earnings multiple in the low? to mid?teens, slightly below the broader healthcare sector average, according to Barchart as of May 4, 2026. This valuation discount, combined with a history of consistent dividend payments and share?buyback activity, has drawn attention from income?oriented and value?oriented investors. However, the stock’s recent underperformance highlights the risks associated with sector rotation, regulatory scrutiny and execution challenges in a complex, capital?intensive industry.

Conclusion

Abbott Laboratories remains a major diversified healthcare company with a broad portfolio of medical devices, diagnostics, nutrition and pharmaceutical products. Recent share?price weakness has pushed the stock to a 52?week low near $86, reflecting both sector?wide headwinds and company?specific earnings volatility, even as insiders have been adding to their positions. Analysts expect modest earnings growth in 2026, with EPS estimates slightly above prior?year levels, but the path forward will depend on Abbott’s ability to sustain innovation, manage regulatory and reimbursement risks and maintain profitability in a competitive environment.

For US investors, Abbott offers exposure to a large, dividend?paying healthcare name with global reach and a long track record of cash generation. However, the stock’s recent volatility and valuation discount also underscore the importance of understanding the company’s complex business mix and the broader healthcare?sector dynamics. As with any equity investment, investors should weigh Abbott’s growth prospects, balance?sheet strength and dividend profile against their own risk tolerance and time horizon.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.